215 related articles for article (PubMed ID: 14747225)
1. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet.
Ludvik B; Neuffer B; Pacini G
Diabetes Care; 2004 Feb; 27(2):436-40. PubMed ID: 14747225
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients.
Ludvik B; Waldhäusl W; Prager R; Kautzky-Willer A; Pacini G
Metabolism; 2003 Jul; 52(7):875-80. PubMed ID: 12870164
[TBL] [Abstract][Full Text] [Related]
3. Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects.
Ludvik B; Hanefeld M; Pacini G
Diabetes Obes Metab; 2008 Jul; 10(7):586-92. PubMed ID: 17645559
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J; Bugos C; Dirnberger G; Atherton T
Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
7. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes.
Albarracin CA; Fuqua BC; Evans JL; Goldfine ID
Diabetes Metab Res Rev; 2008; 24(1):41-51. PubMed ID: 17506119
[TBL] [Abstract][Full Text] [Related]
8. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
Zieve FJ; Kalin MF; Schwartz SL; Jones MR; Bailey WL
Clin Ther; 2007 Jan; 29(1):74-83. PubMed ID: 17379048
[TBL] [Abstract][Full Text] [Related]
9. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
10. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
11. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
[TBL] [Abstract][Full Text] [Related]
12. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
13. Effect of Pancreas Tonic (an ayurvedic herbal supplement) in type 2 diabetes mellitus.
Hsia SH; Bazargan M; Davidson MB
Metabolism; 2004 Sep; 53(9):1166-73. PubMed ID: 15334379
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Barzilai N; Guo H; Mahoney EM; Caporossi S; Golm GT; Langdon RB; Williams-Herman D; Kaufman KD; Amatruda JM; Goldstein BJ; Steinberg H
Curr Med Res Opin; 2011 May; 27(5):1049-58. PubMed ID: 21428727
[TBL] [Abstract][Full Text] [Related]
16. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Fonseca VA; Alvarado-Ruiz R; Raccah D; Boka G; Miossec P; Gerich JE;
Diabetes Care; 2012 Jun; 35(6):1225-31. PubMed ID: 22432104
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
[TBL] [Abstract][Full Text] [Related]
20. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
